Disease · HP_0000458
Anosmia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Anosmia. Diseases, record HP_0000458. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000458
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Anosmia
- Open Targets ID
- HP_0000458
- Other names
- Loss of smell, Lost smell
- Highest stage of its drugs
- Phase 3, for 5 of its 11 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| INSULIN HUMAN | CHEMBL1201631 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ACETYLCYSTEINE | CHEMBL600 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| BUDESONIDE | CHEMBL1370 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| HYALURONIC ACID | CHEMBL5314376 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| MOMETASONE FUROATE | CHEMBL1161 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ELEUTHERO | CHEMBL2108194 | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| IVERMECTIN | CHEMBL6067487 | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| THEOPHYLLINE | CHEMBL1355736 | Protein | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| FISH OIL | CHEMBL3833369 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets12
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ADORA1 | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2 | https://conductscience.org/library/genes/134 | Drugs and targets |
| ADORA2A | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADORA3 | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2 | https://conductscience.org/library/genes/140 | Drugs and targets |
| INSR | Insulin receptor | 1 | Insulin receptor agonist | Phase 3 | https://conductscience.org/library/genes/3643 | Drugs and targets |
| PDE3A | Phosphodiesterase 3 | 1 | Phosphodiesterase 3 inhibitor | Phase 2 | https://conductscience.org/library/genes/5139 | Drugs and targets |
| PDE3B | Phosphodiesterase 3 | 1 | Phosphodiesterase 3 inhibitor | Phase 2 | https://conductscience.org/library/genes/5140 | Drugs and targets |
| PDE4A | Phosphodiesterase 4 | 1 | Phosphodiesterase 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/5141 | Drugs and targets |
| PDE4B | Phosphodiesterase 4 | 1 | Phosphodiesterase 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/5142 | Drugs and targets |
1 to 10 of 12
See all 12 targetsTrials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04495816 | COVID-19 Anosmia Study | Phase 2 | 139 | 2023-01-31 | Anosmia, Covid19 | FISH OIL | Its record names the disease | ClinicalTrials.gov |
| NCT04789499 | Smell in Covid-19 and Efficacy of Nasal Theophylline | Phase 2 | 51 | 2023-05-24 | Covid19, Anosmia, Olfactory Disorder, Covid-19 Pandemic, SARS-CoV-2 Infection, Hyposmia, Ageusia, Hypogeusia | THEOPHYLLINE | Its record names the disease | ClinicalTrials.gov |
| NCT03680911 | NAC for Head Trauma-induced Anosmia | Phase 3 | 7 | 2021-02-04 | Anosmia, Head Trauma | ACETYLCYSTEINE | Its record names the disease | ClinicalTrials.gov |
| NCT04569825 | Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease | Early phase 1 | 250 | Clinical Trial | BETAMETHASONE | Its record names the disease | ClinicalTrials.gov | |
| NCT05328414 | Preparation and Characterization Intranasal Film Loaded With Steroid as a Local Treatment of Anosmia in Compare to Insulin Intranasal Film | Phase 1/2 | 200 | Smell Loss | PREDNISOLONE | Its record names the disease | ClinicalTrials.gov | |
| NCT04847518 | Assessment of Efficacy of KAN-JANG® in Mild COVID-19 | Phase 2/3 | 140 | Covid19 | ELEUTHERO | Its record names the disease | ClinicalTrials.gov | |
| NCT04361474 | Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity | Phase 3 | 120 | Budesonide, Olfaction Disorders, SARS-CoV-2, Anosmia | BUDESONIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04951362 | Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia | Phase 2/3 | 117 | Anosmia | IVERMECTIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04484493 | Corticosteroid Nasal Spray in COVID-19 Anosmia | Phase 3 | 100 | Covid19, Anosmia | MOMETASONE FUROATE | Its record names the disease | ClinicalTrials.gov | |
| NCT06290219 | The Effect of Platelet-rich Plasma Nasal Injection in the Treatment of Traumatic Olfactory Dysfunction | Phase 3 | 80 | Traumatic Olfactory Nerve Injury With Anosmia (Diagnosis), Effect of Drug | HYALURONIC ACID | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Omega-3 vs Placebo/Control: deaths from any cause | 0 of 70 | 0 of 69 | 139 | NCT04495816 | Trial comparisons |
| Omega-3 vs Placebo/Control: serious adverse events | 0 of 70 | 0 of 69 | 139 | NCT04495816 | Trial comparisons |
| Theophylline vs Placebo: deaths from any cause | 0 of 26 | 0 of 25 | 51 | NCT04789499 | Trial comparisons |
| Theophylline vs Placebo: serious adverse events | 0 of 26 | 0 of 25 | 51 | NCT04789499 | Trial comparisons |
| NAC Group vs Placebo Group: deaths from any cause | 0 of 3 | 0 of 4 | 7 | NCT03680911 | Trial comparisons |
| NAC Group vs Placebo Group: serious adverse events | 0 of 3 | 0 of 4 | 7 | NCT03680911 | Trial comparisons |
Papers from its trials11
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000458
GET https://conductscience.org/api/diseases/v1/HP_0000458/drugs